資源描述：
《氯吡格雷治療冠心病的幾個(gè)問題與對(duì)策-魏盟》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在教育資源-天天文庫。
1、氯吡格雷治療冠心病的幾個(gè)問題與對(duì)策上海市第六人民醫(yī)院魏盟UFHADPADP受體抑制劑斑塊破裂血管壁受損白血栓途徑紅血栓途徑VonWillebrand因子、膠原血小板黏附血小板激活纖維蛋白原結(jié)合血小板聚集血栓凝血酶（IIa）組織因子/VIIa因子復(fù)合物L(fēng)MWHXa纖維蛋白原纖維蛋白TXA2阿司匹林纖溶抗栓治療GPIIb/IIIa受體拮抗劑PlateletStimuliGPIIb/IIIaintegrinADPEpinephrineCollagenThrombinPlateletAggregationSerotoninShearrateAATxA2COX-1ThrombinThrom
2、binThrombinTxA2TxA2ThrombinADPTXA2ADPP2Y12ADP(fibrinogenreceptor)GPIIb/IIIaActivationCOX-1clopidogrelbisulfateaspirincAMPOralAnti-PAR-1receptorsSCH530348E5555adaptedfromSchaferAI.AmJMed.1996;101:199-209.氯吡格雷治療若干問題與對(duì)策用藥時(shí)間、劑量、抵抗與新藥氯吡格雷與PPI國(guó)產(chǎn)氯吡格雷循證學(xué)依據(jù)及其意義25,087ACSPatients(UA/NSTEMI70.8%,STEMI29.
3、2%)PlannedEarly(<24h)InvasiveManagementwithintendedPCIIschemicECGΔ(80.8%)or↑c(diǎn)ardiacbiomarker(42%)PCI17,232(70%)Angio24,769(99%)NoPCI7,855(30%)NoSig.CAD3,616CABG1,809CAD2,430Randomizedtoreceive(2X2factorial):CLOPIDOGREL:Double-dose(600mgthen150mg/dx7dthen75mg/d)vsStandarddose(300mgthen75mg/d)A
4、SA:HighDose(300-325mg/d)vsLowdose(75-100mg/d)EfficacyOutcomes:CVDeath,MIorstrokeatday30StentThrombosisatday30SafetyOutcomes:CURRENTdefinedMajor/SevereandTIMIMajorKeySubgroup:PCIvNoPCIClopin1st7d(median)7d7d2d7dCompleteFollowup99.8%Compliance:DaysCumulativeHazard0.00.0040.0080.0120369121518212
5、42730ClopidogrelStandardDoseClopidogrelDoubleDose42%RRRHR0.5895%CI0.42-0.79P=0.001Clopidogrel:DoublevsStandardDoseDefiniteStentThrombosisDaysCumulativeHazard0.00.010.020.030.04036912151821242730Clopidogrel:DoublevsStandardDosePrimaryOutcome:PCIPatientsClopidogrelStandardClopidogrelDoubleHR0.8
6、595%CI0.74-0.99P=0.03615%RRRCVDeath,MIorStrokeDefiniteStentThrombosisin4Groups(AngiographicallyProven)DaysCumulativeHazard0.00.0040.0080.012036912151821242730CStandard,ALowCStandard,AHighCDouble,ALowCDouble,AHighStandardClopDoubleClopHRPPIntnHighASA1.20.60.490.003LowASA1.20.80.60.0580.35Clini
7、calImplicationsForevery1,000patientswithACSreceivingPCI,usingdouble-doseclopidogrelfor7daysinsteadofstandarddosewillpreventanadditional6MI’sand7stentthromboseswithanexcessof3severebleedsandnoincreaseinfatal,CABG-relatedorTIMImajorbleeds.Patie
